Catalyst Pharmaceuticals Income After Taxes 2010-2024 | CPRX

Catalyst Pharmaceuticals income after taxes from 2010 to 2024. Income after taxes can be defined as earnings or losses after income tax expense but before minority interest, extraordinary items, discontinued operations, preferred dividends and accounting changes have been accounted for.
Catalyst Pharmaceuticals Annual Income After Taxes
(Millions of US $)
2024 $164
2023 $71
2022 $83
2021 $39
2020 $75
2019 $32
2018 $-34
2017 $-18
2016 $-18
2015 $-20
2014 $-16
2013 $-12
2012 $-4
2011 $-6
2010 $-4
2009 $-7
Catalyst Pharmaceuticals Quarterly Income After Taxes
(Millions of US $)
2024-12-31 $56
2024-09-30 $44
2024-06-30 $41
2024-03-31 $23
2023-12-31 $35
2023-09-30 $-31
2023-06-30 $38
2023-03-31 $30
2022-12-31 $25
2022-09-30 $23
2022-06-30 $22
2022-03-31 $13
2021-12-31 $9
2021-09-30 $10
2021-06-30 $12
2021-03-31 $8
2020-12-31 $11
2020-09-30 $43
2020-06-30 $10
2020-03-31 $10
2019-12-31 $8
2019-09-30 $14
2019-06-30 $11
2019-03-31 $-1
2018-12-31 $-15
2018-09-30 $-8
2018-06-30 $-6
2018-03-31 $-6
2017-12-31 $-5
2017-09-30 $-4
2017-06-30 $-4
2017-03-31 $-5
2016-12-31 $-4
2016-09-30 $-4
2016-06-30 $-5
2016-03-31 $-5
2015-12-31 $-6
2015-09-30 $-4
2015-06-30 $-5
2015-03-31 $-5
2014-12-31 $-3
2014-09-30 $-5
2014-06-30 $-3
2014-03-31 $-4
2013-12-31 $-1
2013-09-30 $-6
2013-06-30 $-3
2013-03-31 $-2
2012-12-31 $0
2012-09-30 $-3
2012-06-30 $0
2012-03-31 $-1
2011-12-31 $-2
2011-09-30 $-1
2011-06-30 $-1
2011-03-31 $-2
2010-12-31 $-1
2010-09-30 $-1
2010-06-30 $-1
2010-03-31 $-1
2009-12-31 $-1
2009-09-30 $-1
2009-06-30 $-2
2009-03-31 $-3
Sector Industry Market Cap Revenue
Medical MED-DRUGS $3.029B $0.492B
Catalyst Pharmaceuticals, Inc. is a development-stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders, like Lambert-Eaton Myasthenic Syndrome (LEMS), epilepsy and Tourette syndrome. Catalyst in-licensed rights to Firdapse (for treating LEMS) from BioMarin Pharmaceutical Inc. for its development and commercialization in the U.S. Firdapse is currently approved in the European Union and in the U.S. for treating of LEMS in adults. The company also plans to file a supplemental new drug application for Firdapse to treat pediatric patients with LEMS.?The company is also strengthening the commercial portfolio of Firdapse. It has already received multiple patents that cover the treatment of all amifampridine metabolizer types within the LEMS patient population.?Apart from Firdapse, the company is working on a generic version of Lundbeck's Sabril, CPP-109, for the treatment of infantile spasms and complex partial seizures.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) JP $98.106B 36.80
Zoetis (ZTS) US $70.247B 26.59
Daiichi Sankyo, - (DSNKY) JP $49.445B 25.16
Takeda Pharmaceutical (TAK) JP $48.747B 10.79
Summit Therapeutics (SMMT) US $20.720B 0.00
Sandoz Group AG (SDZNY) CH $19.545B 0.00
Merck (MKKGY) DE $18.346B 15.18
Shionogi (SGIOY) JP $14.436B 14.46
United Therapeutics (UTHR) US $13.289B 11.76
Neurocrine Biosciences (NBIX) US $10.852B 33.34
IPSEN (IPSEY) FR $9.920B 0.00
Orion OYJ (ORINY) FI $8.948B 24.20
Corcept Therapeutics (CORT) US $7.717B 58.69
Madrigal Pharmaceuticals (MDGL) US $7.005B 0.00
Stevanato Group S.p.A (STVN) IT $6.475B 41.12
Ono Pharmaceutical (OPHLF) JP $5.988B 12.26
Hikma Pharmaceuticals Plc (HKMPF) GB $5.813B 0.00
Ionis Pharmaceuticals (IONS) US $5.217B 0.00
Grifols, S.A (GRFS) ES $5.054B 0.00
Soleno Therapeutics (SLNO) US $3.755B 0.00
Crinetics Pharmaceuticals (CRNX) US $3.161B 0.00
AMNEAL PHARMACEUTICALS, INC (AMRX) US $2.470B 13.51
Hypermarcas (HYPMY) BR $2.350B 15.46
Recursion Pharmaceuticals (RXRX) US $2.291B 0.00
NewAmsterdam Pharma (NAMS) NL $2.200B 0.00
BioCryst Pharmaceuticals (BCRX) US $1.868B 0.00
Centessa Pharmaceuticals (CNTA) GB $1.813B 0.00
Indivior (INDV) US $1.652B 7.01
Guardian Pharmacy Services (GRDN) US $1.632B 0.00
Evotec AG (EVO) DE $1.523B 0.00
ARS Pharmaceuticals (SPRY) US $1.420B 180.75
Ocular Therapeutix (OCUL) US $1.402B 0.00
Dyne Therapeutics (DYN) US $1.348B 0.00
Aurinia Pharmaceuticals Inc (AUPH) CA $1.122B 45.61
Enliven Therapeutics (ELVN) US $1.006B 0.00
Ardelyx (ARDX) US $0.984B 0.00
Harrow (HROW) US $0.948B 0.00
Collegium Pharmaceutical (COLL) US $0.888B 4.72
Avadel Pharmaceuticals (AVDL) IE $0.840B 0.00
Xencor (XNCR) US $0.801B 0.00
AleAnna (ANNA) US $0.758B 0.00
Xeris Biopharma Holdings (XERS) US $0.737B 0.00
Cronos Group (CRON) CA $0.709B 0.00
KalVista Pharmaceuticals (KALV) US $0.674B 0.00
Organogenesis (ORGO) US $0.670B 0.00
Akebia Therapeutics (AKBA) US $0.641B 0.00
Bioventus (BVS) US $0.601B 15.62
Savara (SVRA) US $0.587B 0.00
USANA Health Sciences (USNA) US $0.555B 11.92
Relay Therapeutics (RLAY) US $0.554B 0.00
Regulus Therapeutics (RGLS) US $0.520B 0.00
Theravance Biopharma (TBPH) KY $0.519B 0.00
Amylyx Pharmaceuticals (AMLX) US $0.474B 0.00
Verve Therapeutics (VERV) US $0.463B 0.00
Elite Pharmaceuticals (ELTP) US $0.453B 0.00
Altimmune (ALT) US $0.444B 0.00
Zevra Therapeutics (ZVRA) US $0.437B 0.00
Tourmaline Bio (TRML) US $0.419B 0.00
CytoDyn (CYDY) US $0.405B 0.00
Siga Technologies (SIGA) US $0.402B 6.87
Oruka Therapeutics (ORKA) US $0.401B 0.00
Heron Therapeutics (HRTX) US $0.352B 0.00
Rigel Pharmaceuticals (RIGL) US $0.346B 20.60
Aquestive Therapeutics (AQST) US $0.298B 0.00
Avita Medical (RCEL) US $0.244B 0.00
Wellgistics Health (WGRX) US $0.232B 0.00
ProKidney (PROK) US $0.231B 0.00
Nature's Sunshine Products (NATR) US $0.231B 27.15
Esperion Therapeutics (ESPR) US $0.216B 27.25
OmniAb (OABI) US $0.214B 0.00
Korro Bio (KRRO) US $0.197B 0.00
Larimar Therapeutics (LRMR) US $0.190B 0.00
MediWound (MDWD) IL $0.186B 0.00
4D Molecular Therapeutics (FDMT) US $0.174B 0.00
Aldeyra Therapeutics (ALDX) US $0.168B 0.00
Inhibikase Therapeutics (IKT) US $0.167B 0.00
Journey Medical (DERM) US $0.162B 0.00
Nanobiotix S.A (NBTX) FR $0.157B 0.00
Profound Medical (PROF) CA $0.157B 0.00
Aclaris Therapeutics (ACRS) US $0.156B 0.00
Lexeo Therapeutics (LXEO) US $0.154B 0.00
Ironwood Pharmaceuticals (IRWD) US $0.151B 46.61
Procaps Group, S.A (PROCF) LU $0.141B 0.00
Nektar Therapeutics (NKTR) US $0.140B 0.00
Protara Therapeutics (TARA) US $0.138B 0.00
Lyell Immunopharma (LYEL) US $0.136B 0.00
Tonix Pharmaceuticals Holding (TNXP) US $0.129B 0.00
Enanta Pharmaceuticals (ENTA) US $0.127B 0.00
Innate Pharma SA (IPHYF) FR $0.122B 0.00
VAXART, INC (VXRT) US $0.103B 0.00
Corbus Pharmaceuticals Holdings (CRBP) US $0.095B 0.00
OptiNose (OPTN) US $0.095B 0.00
Cardiol Therapeutics (CRDL) CA $0.094B 0.00
Achieve Life Sciences (ACHV) CA $0.089B 0.00
Galectin Therapeutics (GALT) US $0.088B 0.00
Arch Biopartners (ACHFF) CA $0.083B 0.00
Dominari Holdings (DOMH) US $0.083B 0.00
Champions Oncology (CSBR) US $0.080B 13.11
Unicycive Therapeutics (UNCY) US $0.078B 0.00
Pyxis Oncology (PYXS) US $0.078B 0.00
Context Therapeutics (CNTX) US $0.078B 0.00
Cassava Sciences (SAVA) US $0.078B 0.00
Fractyl Health (GUTS) US $0.077B 0.00
Telomir Pharmaceuticals (TELO) US $0.077B 0.00
ESSA Pharma (EPIX) CA $0.077B 0.00
Nutriband (NTRB) US $0.071B 0.00
Inotiv (NOTV) US $0.068B 0.00
Karyopharm Therapeutics (KPTI) US $0.063B 0.00
Cumberland Pharmaceuticals (CPIX) US $0.063B 0.00
Assertio Holdings (ASRT) US $0.062B 0.00
Vivani Medical (VANI) US $0.062B 0.00
Gain Therapeutics (GANX) US $0.061B 0.00
Metagenomi (MGX) US $0.060B 0.00
Allergy Therapeutics (AGYTF) GB $0.059B 0.00
Avalo Therapeutics (AVTX) US $0.054B 0.00
PMV Pharmaceuticals (PMVP) US $0.052B 0.00
ElectroCore (ECOR) US $0.049B 0.00
Century Therapeutics (IPSC) US $0.047B 0.00
Mural Oncology (MURA) IE $0.046B 0.00
Acrivon Therapeutics (ACRV) US $0.044B 0.00
Verrica Pharmaceuticals (VRCA) US $0.043B 0.00
Reviva Pharmaceuticals Holdings (RVPH) US $0.041B 0.00
SCYNEXIS (SCYX) US $0.040B 0.00
Iterum Therapeutics (ITRM) IE $0.039B 0.00
Prelude Therapeutics (PRLD) US $0.039B 0.00
Rafael Holdings (RFL) US $0.038B 0.00
NRx Pharmaceuticals (NRXP) US $0.035B 0.00
FibroGen (FGEN) US $0.034B 0.00
Surrozen (SRZN) US $0.033B 0.00
PolyPid (PYPD) IL $0.028B 0.00
Tempest Therapeutics (TPST) US $0.026B 0.00
CASI Pharmaceuticals (CASI) CN $0.024B 0.00
BioVie (BIVI) US $0.022B 0.00
Enlivex Therapeutics (ENLV) IL $0.022B 0.00
Jupiter Neurosciences (JUNS) US $0.021B 0.00
VYNE Therapeutics (VYNE) US $0.021B 0.00
Mannatech (MTEX) US $0.020B 7.75
DURECT (DRRX) US $0.019B 0.00
Natural Alternatives (NAII) US $0.018B 0.00
Lipocine (LPCN) US $0.018B 0.00
GlycoMimetics (GLYC) US $0.017B 0.00
TherapeuticsMD (TXMD) US $0.016B 0.00
Vivos Therapeutics (VVOS) US $0.016B 0.00
MARKER THERAPEUTICS, INC (MRKR) US $0.014B 0.00
ProPhase Labs (PRPH) US $0.014B 0.00
MEI Pharma (MEIP) US $0.014B 0.00
Cosmos Health (COSM) US $0.012B 0.00
Relmada Therapeutics (RLMD) US $0.012B 0.00
TransCode Therapeutics (RNAZ) US $0.012B 0.00
Scienture Holdings (SCNX) US $0.012B 0.00
Minerva Neurosciences (NERV) US $0.012B 8.95
BioLineRx (BLRX) IL $0.011B 0.00
Plus Therapeutics (PSTV) US $0.011B 0.00
Ernexa Therapeutics (ERNA) US $0.011B 0.00
Carisma Therapeutics (CARM) US $0.010B 0.00
Kiora Pharmaceuticals (KPRX) US $0.010B 3.19
Phio Pharmaceuticals (PHIO) US $0.009B 0.00
Biomerica (BMRA) US $0.009B 0.00
Talphera (TLPH) US $0.009B 0.00
Jaguar Animal Health (JAGX) US $0.009B 0.00
Mangoceuticals (MGRX) US $0.009B 0.00
Addex Therapeutics (ADXN) CH $0.009B 0.00
Ainos (AIMD) US $0.008B 0.00
Nuvilex (PMCB) US $0.008B 0.00
XTL Biopharmaceuticals (XTLB) IL $0.008B 0.00
Traws Pharma (TRAW) US $0.008B 0.00
Citius Pharmaceuticals (CTXR) US $0.008B 0.00
Indaptus Therapeutics (INDP) US $0.007B 0.00
Lyra Therapeutics (LYRA) US $0.007B 0.00
Conduit Pharmaceuticals (CDT) US $0.006B 0.00
NLS Pharmaceutics (NLSP) CH $0.006B 0.00
Sonoma Pharmaceuticals (SNOA) US $0.005B 0.00
Aptorum Group (APM) GB $0.005B 0.00
Klotho Neurosciences (KLTO) US $0.005B 0.00
CERo Therapeutics Holdings (CERO) US $0.005B 0.00
Clearmind Medicine (CMND) CA $0.004B 0.00
Xenetic Biosciences (XBIO) US $0.004B 0.00
Alaunos Therapeutics (TCRT) US $0.004B 0.00
XORTX Therapeutics (XRTX) CA $0.004B 0.00
InMed Pharmaceuticals (INM) CA $0.004B 0.00
Redhill Biopharma (RDHL) IL $0.004B 0.00
Quoin Pharmaceuticals (QNRX) US $0.004B 0.00
60 Degrees Pharmaceuticals (SXTP) US $0.003B 0.00
SciSparc (SPRC) IL $0.003B 0.00
Qualigen Therapeutics (QLGN) US $0.003B 0.00
Incannex Healthcare (IXHL) AU $0.002B 0.00
Galmed Pharmaceuticals (GLMD) IL $0.002B 0.00
PainReform (PRFX) IL $0.002B 0.00
TNF Pharmaceuticals (TNFA) US $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) US $0.002B 0.00
China SXT Pharmaceuticals (SXTC) CN $0.002B 0.00
SHINECO (SISI) CN $0.002B 0.00
Salarius Pharmaceuticals (SLRX) US $0.001B 0.00
Heatwurx (PCSA) US $0.001B 0.00
Petros Pharmaceuticals (PTPI) US $0.001B 0.00
Universe Pharmaceuticals INC (UPC) CN $0.000B 0.00
Aditxt (ADTX) US $0.000B 0.00
4D Pharma (LBPS) GB $0.000B 0.00
Patheon (PTHN) NL $0.000B 0.00
RVL Pharmaceuticals (RVLP) US $0.000B 0.00
Silence Therapeutics (SLN) GB $0.000B 0.00